BGB-3111-305

Completed

A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

Beigene Study ID info

BGB-3111-305

ClinicalTrials.gov ID info

EudraCT Number info

2018-001366-42

China Drug Trials ID info

CTR20190098

Study Overview

Sex: All

Age: 18 Years / N/A

Study Documents

Study Protocol and Statistical Analysis Plan

Study Overview

Sex: All

Age: 18 Years / N/A

Study Documents

Study Protocol and Statistical Analysis Plan